Capital Investment Counsel Inc’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$250K Sell
10,372
-200
-2% -$5.23K 0.03% 183
2026
Q1
$297K Buy
10,572
+1,700
+19% +$45.3K 0.04% 158
2025
Q4
$221K Sell
8,872
-2,600
-23% -$65.6K 0.03% 187
2025
Q3
$292K Sell
11,472
-1,650
-13% -$40.7K 0.04% 158
2025
Q2
$318K Sell
13,122
-1,301
-9% -$30.3K 0.04% 151
2025
Q1
$365K Sell
14,423
-9,230
-39% -$242K 0.05% 132
2024
Q4
$628K Sell
23,653
-6,696
-22% -$182K 0.09% 99
2024
Q3
$878K Sell
30,349
-1,433
-5% -$41.8K 0.13% 90
2024
Q2
$889K Sell
31,782
-13,553
-30% -$373K 0.13% 85
2024
Q1
$1.26M Sell
45,335
-14,182
-24% -$394K 0.22% 69
2023
Q4
$1.71M Sell
59,517
-3,963
-6% -$120K 0.3% 58
2023
Q3
$2.11M Hold
63,480
0.42% 45
2023
Q2
$2.33M Buy
63,480
+204
+0.3% +$7.94K 0.45% 42
2023
Q1
$2.58M Sell
63,276
-1,400
-2% -$60.5K 0.59% 38
2022
Q4
$3.31M Buy
64,676
+20,668
+47% +$991K 0.78% 29
2022
Q3
$1.93M Sell
44,008
-21,268
-33% -$1.03M 0.56% 42
2022
Q2
$3.42M Sell
65,276
-361
-0.5% -$18.4K 0.85% 29
2022
Q1
$3.4M Sell
65,637
-1,400
-2% -$72.6K 0.71% 32
2021
Q4
$3.96M Sell
67,037
-7,455
-10% -$369K 0.74% 27
2021
Q3
$3.2M Buy
74,492
+333
+0.4% +$14.8K 0.7% 32
2021
Q2
$2.9M Buy
74,159
+46,620
+169% +$1.81M 0.65% 34
2021
Q1
$998K Buy
27,539
+16,502
+150% +$586K 0.27% 66
2020
Q4
$406K Sell
11,037
-18,305
-62% -$671K 0.13% 90
2020
Q3
$1.02M Buy
29,342
+17,709
+152% +$621K 0.3% 51
2020
Q2
$361K Sell
11,633
-16,655
-59% -$566K 0.14% 87
2020
Q1
$876K Buy
28,288
+2,560
+10% +$87.2K 0.35% 49
2019
Q4
$956K Sell
25,728
-35
-0.1% -$1.25K 0.31% 62
2019
Q3
$878K Sell
25,763
-609
-2% -$22.1K 0.31% 66
2019
Q2
$1.08M Buy
26,372
+983
+4% +$39K 0.39% 56
2019
Q1
$1.02M Buy
25,389
+527
+2% +$21.1K 0.38% 54
2018
Q4
$1.03M Hold
24,862
0.45% 51
2018
Q3
$1.04M Sell
24,862
-557
-2% -$21.4K 0.38% 60
2018
Q2
$875K Sell
25,419
-1,902
-7% -$65K 0.35% 67
2018
Q1
$920K Buy
27,321
+88
+0.3% +$3.02K 0.38% 63
2017
Q4
$936K Sell
27,233
-158
-0.6% -$5.39K 0.39% 63
2017
Q3
$928K Sell
27,391
-3,277
-11% -$105K 0.4% 62
2017
Q2
$977K Sell
30,668
-2,402
-7% -$75.7K 0.43% 59
2017
Q1
$1.07M Buy
33,070
+1,076
+3% +$33.9K 0.48% 55
2016
Q4
$986K Sell
31,994
-290
-0.9% -$8.85K 0.48% 55
2016
Q3
$1.04M Sell
32,284
-2,424
-7% -$81.1K 0.52% 51
2016
Q2
$1.16M Sell
34,708
-106
-0.3% -$3.38K 0.6% 45
2016
Q1
$979K Sell
34,814
-474
-1% -$13.5K 0.5% 50
2015
Q4
$1.08M Sell
35,288
-1,107
-3% -$34.8K 0.56% 47
2015
Q3
$1.08M Sell
36,395
-712
-2% -$22.8K 0.59% 46
2015
Q2
$1.18M Buy
37,107
+317
+0.9% +$10.3K 0.59% 51
2015
Q1
$1.21M Sell
36,790
-221
-0.6% -$7.03K 0.57% 51
2014
Q4
$1.09M Sell
37,011
-1,792
-5% -$51.4K 0.53% 55
2014
Q3
$1.09M Sell
38,803
-5,692
-13% -$160K 0.54% 53
2014
Q2
$1.25M Sell
44,495
-2,893
-6% -$82.5K 0.54% 54
2014
Q1
$1.44M Buy
47,388
+48
+0.1% +$1.43K 0.64% 49
2013
Q4
$1.38M Sell
47,340
-317
-0.7% -$9.23K 0.62% 48
2013
Q3
$1.3M Sell
47,657
-2,318
-5% -$63.1K 0.64% 45
2013
Q2
$1.33M Buy
+49,975
New +$1.38M 0.69% 38

Other funds holding PFE

Capital Investment Counsel Inc's PFE Position: Q2 2026 in Review

Capital Investment Counsel Inc reduced its Pfizer (PFE) stake by 1.9% in Q2 2026, selling an estimated $5.23K and leaving 10,372 shares worth $250K. The position accounts for 0.03% of the portfolio, ranked #183.

Capital Investment Counsel Inc first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.96M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Capital Investment Counsel Inc held 10,372 shares of Pfizer worth $250K as of Q2 2026.
  • Capital Investment Counsel Inc sold 200 Pfizer shares in Q2 2026, an estimated $5.23K.
  • Pfizer made up 0.03% of Capital Investment Counsel Inc's portfolio in Q2 2026, its #183 holding.
  • Capital Investment Counsel Inc first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Capital Investment Counsel Inc's Pfizer position peaked at $3.96M in Q4 2021.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Capital Investment Counsel Inc's 13F filing for Q2 2026, filed 27 Jul 2026.